Somaxon Pharma (SOMX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-8.79M
Share-based compensation expense	1.95M
Depreciation	221K
Amortization	149K
Amortization of investment discount	0
Realized gain on sale of short-term investments	0
Loss on disposal of equipment
Accounts receivable	660K
Inventory	13K
Other current and non-current assets	374K
Accounts payable	-98K
Accrued liabilities	-1.55M
Deferred revenue
Net cash used in operating activities	-5.56M
Purchases of property and equipment	0
Payments for intangible assets	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net cash provided by (used in) investing activities	201K
Issuance of common stock, net of costs	2.85M
Exercise of warrants	0
Exercise of stock options	0
Purchase of treasury stock
Net cash provided by financing activities	2.85M
Increase in cash and cash equivalents	-2.51M
Cash and cash equivalents at beginning of the period	10.67M
Cash and cash equivalents at end of the period	8.16M
Common stock issued to settle severance obligation

Entities mentioned with SOMX

View All Entities